98%
921
2 minutes
20
Purpose: This study aims to develop liposomal formulations containing synergistic antibiotics of colistin and ciprofloxacin for the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa.
Methods: Colistin (Col) and ciprofloxacin (Cip) were co-encapsulated in anionic liposomes by ammonium sulfate gradient. Particle size, encapsulation efficiency, in vitro drug release and in vitro antibiotic activities were evaluated.
Results: The optimized liposomal formulation has uniform sizes of approximately 100 nm, with encapsulation efficiency of 67.0% (for colistin) and 85.2% (for ciprofloxacin). Incorporation of anionic lipid (DMPG) markedly increased encapsulation efficiency of colistin (from 5.4 to 67.0%); however, the encapsulation efficiency of ciprofloxacin was independent of DMPG ratio. Incorporation of colistin significantly accelerated the release of ciprofloxacin from the DMPG anionic liposomes. In vitro release of ciprofloxacin and colistin in the bovine serum for 2 h were above 70 and 50%. The cytotoxicity study using A549 cells showed the liposomal formulation is as non-toxic as the drug solutions. Liposomal formulations of combinations had enhanced in vitro antimicrobial activities against multidrug resistant P. aeruginosa than the monotherapies.
Conclusions: Liposomal formulations of two synergistic antibiotics was promising against multidrug resistant P. aeruginosa infections.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122860 | PMC |
http://dx.doi.org/10.1007/s11095-018-2464-8 | DOI Listing |
Recent Pat Anticancer Drug Discov
September 2025
School of Pharmacy, Devi Ahilya Vishwavidalaya, Indore, M.P., India.
Artemisinin, a natural compound derived from Artemisia annua, has significantly impacted the treatment of malaria and has shown promise in various other therapeutic applications. This review explores the molecular structure of artemisinin and its derivatives, as well as advancements in synthetic and semi-synthetic production methods, and their broader therapeutic effects beyond malaria, including potential uses in cancer, neurological disorders, and viral infections. It also discusses contemporary drug delivery innovations, such as nanoparticles and liposomal systems, which aim to enhance the bioavailability and targeted action of artemisinin, while addressing issues of drug resistance, particularly in parasitic diseases like malaria.
View Article and Find Full Text PDFBioorg Med Chem Lett
September 2025
Department of Chemistry, Taras Shevchenko National University of Kyiv, Kyiv 01601, Ukraine. Electronic address:
Phospholipid-derived nanocarriers represent a versatile and chemically customizable class of drug delivery systems that self-assemble into bilayered vesicles due to their intrinsic amphiphilicity. These systems can encapsulate both hydrophilic and hydrophobic drugs through non-covalent interactions and manipulation of lipid phase behavior. This review examines the molecular and supramolecular principles underlying the formation, stability, and functional performance of key phospholipid-based nanocarriers-including liposomes, transferosomes, ethosomes, invasomes, phytosomes, pharmacosomes, and virosomes.
View Article and Find Full Text PDFCarbohydr Polym
November 2025
Department of Pharmaceutical Analysis, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, Maharashtra 400056, India. Electronic address:
Gum Arabic (GA), a naturally occurring polysaccharide, has emerged as a promising biomaterial for drug delivery systems (DDS) due to its high water solubility, emulsifying capacity, biocompatibility, and biodegradability. Its structural richness in arabinogalactan facilitates strong interactions with biomolecules, enabling the development of various drug formulations including hydrogels, nanoparticles, liposomes, and emulsions. GA-based DDS have demonstrated significant potential in enhancing the solubility of poorly water-soluble drugs, protecting bioactive compounds from degradation, and enabling sustained and controlled drug release.
View Article and Find Full Text PDFJ Drug Target
September 2025
Department of Pharmaceutics, Division of Pharmaceutical Sciences, College of Pharmacy, Arab Academy for Science, Technology and Maritime Transport, Alexandria, P.O. Box 1029, Egypt.
Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes joint inflammation, cartilage deterioration, and oxidative stress. The study developed transdermal RA treatment with L-carnosine (CAR)-loaded chondroitin sulfate (CHS) functionalized proposomes. CHS-functionalized proposomes measured 285 ± 0.
View Article and Find Full Text PDFNanomedicine (Lond)
September 2025
Département des Technologies pour l'Innovation en Santé, Université Grenoble-Alpes, CEA-LETI, Grenoble, France.
Lung cancer remains the leading cause of cancer-related deaths worldwide, with limited curative options, particularly in advanced stages. Lipid-based nanocarriers, including liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and lipid nanocapsules (LNCs), have emerged as promising drug delivery platforms owing to their biocompatibility, versatility, and potential for pulmonary administration. This review highlights recent advances in lipid nanocarriers for lung cancer therapy, with a particular focus on NLCs and LNCs.
View Article and Find Full Text PDF